4.6 Article

Genetic, Immunological, and Clinical Features of the First Mexican Cohort of Patients with Chronic Granulomatous Disease

Journal

JOURNAL OF CLINICAL IMMUNOLOGY
Volume 40, Issue 3, Pages 475-493

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-020-00750-5

Keywords

Chronic granulomatous disease; NADPH oxidase; recurrent infection; mycobacteria

Categories

Funding

  1. FUMENI A.C.
  2. SNI-CONACYT fellowships
  3. Rockefeller University
  4. Foundation for Medical Research (FRM)
  5. St. Giles Foundation
  6. French National Institute of Health and Medical Research (INSERM), Paris University
  7. Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence [ANR-10-LABX-62-IBEID]
  8. French National Research Agency under the Investments for the future program [ANR-10-IAHU-01]
  9. ANR-GENMSMD [ANR-16-CE17-0005-01]
  10. [CONACYT-SALUD-2012-01-180910]
  11. Agence Nationale de la Recherche (ANR) [ANR-16-CE17-0005] Funding Source: Agence Nationale de la Recherche (ANR)

Ask authors/readers for more resources

Purpose Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by an inability of phagocytes to produce reactive oxygen species, impairing their killing of various bacteria and fungi. We summarize here the 93 cases of CGD diagnosed in Mexico from 2011 to 2019. Methods Thirteen Mexican hospitals participated in this study. We describe the genetic, immunological, and clinical features of the 93 CGD patients from 78 unrelated kindreds. Results Eighty-two of the patients (88%) were male. All patients developed bacterial infections and 30% suffered from some kind of fungal infection. Fifty-four BCG-vaccinated patients (58%) presented infectious complications of BCG vaccine. Tuberculosis occurred in 29%. Granulomas were found in 56% of the patients. Autoimmune and inflammatory diseases were present in 15% of patients. A biological diagnosis of CGD was made in 89/93 patients, on the basis of NBT assay (n = 6), DHR (n = 27), and NBT plus DHR (n = 56). The deficiency was complete in all patients. The median age of biological diagnosis was 17 months (range, 0-186 months). A genetic diagnosis was made in 83/93 patients (when material was available), corresponding to CYBB (n = 64), NCF1 (n = 7), NCF2 (n = 7), and CYBA (n = 5) mutations. Conclusions The clinical manifestations in these Mexican CGD patients were similar to those in patients elsewhere. This cohort is the largest in Latin America. Mycobacterial infections are an important cause of morbidity in Mexico, as in other countries in which tuberculosis is endemic and infants are vaccinated with BCG. X-linked CGD accounted for most of the cases in Mexico, as in other Latin American countries. However, a significant number of CYBA and NCF2 mutations were identified, expanding the spectrum of known causal mutations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available